checkAd

     934  0 Kommentare Theravance Biopharma Highlights Acceleration of Timeline for Filing U.S. New Drug Application for the Closed Triple by GlaxoSmithKline and Innoviva - Seite 3

    Contact Information:

    Renee Gala
    Chief Financial Officer
    650-808-4045
    investor.relations@theravance.com

    Tim Brons
    Vida Strategic Partners (media)
    646-319-8981
    tbrons@vidasp.com

    Lesen Sie auch


    Seite 3 von 3

    Verfasst von Marketwired
    3 im Artikel enthaltene WerteIm Artikel enthaltene Werte
    Theravance Biopharma Highlights Acceleration of Timeline for Filing U.S. New Drug Application for the Closed Triple by GlaxoSmithKline and Innoviva - Seite 3 DUBLIN, IRELAND--(Marketwired - Jun 2, 2016) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced that GlaxoSmithKline plc (GSK) and Innoviva, Inc. (Innoviva) have accelerated the timeline for filing a New Drug …